{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:58:01Z","timestamp":1786121881295,"version":"build-2736575974"},"reference-count":23,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Petrelintide is a long\u2010acting amylin analogue in development for weight management. The safety, tolerability, pharmacokinetics, and pharmacodynamics of petrelintide were evaluated in single ascending dose (SAD) and multiple ascending dose (MAD) trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Both trials were randomized, placebo\u2010controlled, and double\u2010blind. The SAD trial assessed subcutaneous (SC) petrelintide doses of 0.04\u20132.4\u2009mg and a 0.35\u2009mg intravenous dose. The MAD trial evaluated 6 once\u2010weekly SC doses of 0.6 and 1.2\u2009mg (part 1), and 16 once\u2010weekly doses escalated every 2\u2009weeks to target doses of 2.4, 4.8, and 9.0\u2009mg (part 2). The SAD and MAD part 1 trials enrolled normal or overweight adults; MAD part 2 enrolled adults with overweight or obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Petrelintide was well tolerated, with no serious or severe treatment\u2010emergent adverse events (TEAEs). In both trials, the most common TEAEs included gastrointestinal (GI) disorders, most of which were mild. One participant discontinued treatment due to GI TEAEs. Nausea, the most common GI TEAE, occurred in 16.7%\u201333.3% of participants receiving petrelintide versus 16.7% for placebo in MAD part 2, while diarrhoea was rare and vomiting was only experienced by the participant who discontinued. Petrelintide was slowly absorbed, had a half\u2010life of ~10\u2009days, showed steady\u2010state dose proportionality, and reduced body weight by up to 8.6% after 16\u2009weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Petrelintide appeared safe, had a low incidence of GI TEAEs, and resulted in clinically relevant weight loss. These findings support further development of petrelintide as an effective weight\u2010management medication, with potential for improved GI tolerability over existing therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70753","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:18:28Z","timestamp":1776849508000},"page":"5915-5925","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7244-571X","authenticated-orcid":false,"given":"Minna","family":"Br\u00e6ndholt Olsen","sequence":"first","affiliation":[{"name":"Zealand Pharma A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Griffin","sequence":"additional","affiliation":[{"name":"Zealand Pharma A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0940-8972","authenticated-orcid":false,"given":"Ulrike","family":"H\u00f6velmann","sequence":"additional","affiliation":[{"name":"Profil  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislava","family":"Macura","sequence":"additional","affiliation":[{"name":"Zealand Pharma A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berith","family":"Fredsted Hagen","sequence":"additional","affiliation":[{"name":"Zealand Pharma A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Hesse","sequence":"additional","affiliation":[{"name":"Zealand Pharma A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8346-2037","authenticated-orcid":false,"given":"Tim","family":"Heise","sequence":"additional","affiliation":[{"name":"Profil  Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01604-7"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.15605\/jafes.037.02.14"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1085799"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02597-w"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-025-01859-6"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.22284"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-21061-z"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03095-3"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP161365.GL"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00316-4"},{"key":"e_1_2_10_14_1","volume-title":"World Obesity Atlas","author":"World Obesity Federation","year":"2025"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)02155-5"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502081"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c01185"},{"key":"e_1_2_10_18_1","unstructured":"B.Vestergaard \u201cPetrelintide Induced Potent Additional Weight Loss in Combination With Either Semaglutide or Tirzepatide in DIO Rats. Presented at the 60th EASD Annual Meeting 2024:Oral Presentation #78\u201d."},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15728"},{"key":"e_1_2_10_20_1","unstructured":"European Medicines Agency (EMA). Committee for Medicinal Products for Human Use \u201cGuideline on Strategies to Identify and Mitigate Risks for First\u2010in\u2010human and Early Clinical Trials With Investigational Medicinal Products\u201d(2017) https:\/\/www.ema.europa.eu\/en\/strategies\u2010identify\u2010mitigate\u2010risks\u2010first\u2010human\u2010early\u2010clinical\u2010trials\u2010investigational\u2010medicinal\u2010products\u2010scientific\u2010guideline."},{"key":"e_1_2_10_21_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research \u201cGuidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers\u201d(2005) https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/estimating\u2010maximum\u2010safe\u2010starting\u2010dose\u2010initial\u2010clinical\u2010trials\u2010therapeutics\u2010adult\u2010healthy\u2010volunteers."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2025.110587"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/db25-882-P"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01751-7"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.70753","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.70753","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.70753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T07:33:37Z","timestamp":1786088017000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.70753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/dom.70753"],"URL":"https:\/\/doi.org\/10.1111\/dom.70753","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.70753\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70753\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70753\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70753\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70753\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70753\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70753\/v2\/review1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"2026-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}